Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra L Cox

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Drugs of Today (Barcelona, Spain : 1998)|October 29, 2004
Rosiglitazone maleate/metformin hydrochloride: a new formulation therapy for type 2 diabetesSandra L Cox
Drugs of Today (Barcelona, Spain : 1998)|September 30, 2005
Insulin glulisineSandra L Cox
Drugs of Today (Barcelona, Spain : 1998)|December 13, 2005
Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemiaSandra L Cox
Drugs of Today (Barcelona, Spain : 1998)|October 20, 2005
Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factorsSandra L Cox
Drugs of Today (Barcelona, Spain : 1998)|April 22, 2006
Tesaglitazar: a promising approach in type 2 diabetesSandra L Cox
Drugs of Today (Barcelona, Spain : 1998)|July 22, 2005
Emtricitabine: a novel nucleoside reverse transcriptase inhibitorJean-Michel Molina, Sandra L Cox
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Drugs of Today (Barcelona, Spain : 1998)|October 29, 2004
Rosiglitazone maleate/metformin hydrochloride: a new formulation therapy for type 2 diabetesSandra L Cox
Drugs of Today (Barcelona, Spain : 1998)|September 30, 2005
Insulin glulisineSandra L Cox
Drugs of Today (Barcelona, Spain : 1998)|December 13, 2005
Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemiaSandra L Cox
Drugs of Today (Barcelona, Spain : 1998)|October 20, 2005
Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factorsSandra L Cox
Drugs of Today (Barcelona, Spain : 1998)|April 22, 2006
Tesaglitazar: a promising approach in type 2 diabetesSandra L Cox
Drugs of Today (Barcelona, Spain : 1998)|July 22, 2005
Emtricitabine: a novel nucleoside reverse transcriptase inhibitorJean-Michel Molina, Sandra L Cox
Pageof 1